References
- CDC. Methicillin-resistant Staphylococcus aureus infections in correctional facilities—Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003; 52:992-6
- Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, Boo T, McAllister S, Anderson J, Jensen B, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352:468-75; PMID:15689585; https://doi.org/http://dx.doi.org/10.1056/NEJMoa042859
- Zinderman CE, Conner B, Malakooti MA, LaMar JE, Armstrong A, Bohnker BK. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis 2004; 10:941-4; PMID:15200838; https://doi.org/http://dx.doi.org/10.3201/eid1005.030604
- Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004; 39:971-9; PMID:15472848; https://doi.org/http://dx.doi.org/10.1086/423965
- Ellis MW, Griffith ME, Jorgensen JH, Hospenthal DR, Mende K, Patterson JE. Presence and molecular epidemiology of virulence factors in methicillin-resistant Staphylococcus aureus strains colonizing and infecting soldiers. J Clin Microbiol 2009; 47:940-5; PMID:19213694; https://doi.org/http://dx.doi.org/10.1128/JCM.02352-08
- Co E, Keen EF, Aldous WK. Prevalence of methicillin-resistant Staphylococcus aureus in a combat support hospital in Iraq. Military Medicine 2011; 176:89-93; PMID:21305966; https://doi.org/http://dx.doi.org/10.7205/MILMED-D-09-00126
- Huang X, Cash DM, Chahine MA, van Horn GT, Erwin DP, McKay JT, Hamilton LR, Jerke KH, Co EA, Aldous WK, et al. Methicillin-resistant Staphylococcus aureus infection in combat support hospitals in three regions of Iraq. Epidemiol Infect 2011; 139:994-7; PMID:20727246; https://doi.org/http://dx.doi.org/10.1017/S0950268810001950
- Landrum ML, Neumann C, Cook C, Chukwuma U, Ellis MW, Hospenthal DR, Murray CK. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA 2012; 308:50-9; PMID:22760291; https://doi.org/http://dx.doi.org/10.1001/jama.2012.7139
- Ellis MW, Griffith ME, Dooley DP, McLean JC, Jorgensen JH, Patterson JE, Davis KA, Hawley JS, Regules JA, Rivard RG, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 2007; 51:3591-8; PMID:17682105; https://doi.org/http://dx.doi.org/10.1128/AAC.01086-06
- Whitman TJ, Herlihy RK, Schlett CD, Murray PR, Grandits GA, Ganesan A, Brown M, Mancuso JD, Adams WB, Tribble DR. Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in Marine recruits: a cluster-randomized, double-blind, controlled effectiveness trial. Infect Control Hosp Epidemiol 2010; 31:1207-15; PMID:21028984; https://doi.org/http://dx.doi.org/10.1086/657136
- Army Medical Surveillance Activity. Hospitalizations among members of the active component, US. Armed Forces, 2014. Medical Surveillance Monthly Report 2015; 22:11-17 Medical Surveillance Monthly Report:11-7
- Army Medical Surveillance Activity. Ambulatory Visits Among Members of the Active Component, U.S Armed Forces, 2014. Medical Surveillance Monthly Report 2015; 22:19-24
- Deresinski S. Antistaphylococcal vaccines and immunoglobulins: current status and future prospects. Drugs 2006; 66:1797-806; PMID:17040111; https://doi.org/http://dx.doi.org/10.2165/00003495-200666140-00002
- Holtfreter S, Kolata J, Broker BM. Towards the immune proteome of Staphylococcus aureus- the anti-S. aureus antibody response. Int J Med Microbiol 2010; 300:176-92; PMID:19889576; https://doi.org/http://dx.doi.org/10.1016/j.ijmm.2009.10.002
- Otto M. Targeted immunotherapy for staphylococcal infections: focus on anti-MSCRAMM antibodies. BioDrugs 2008; 22:27-36; PMID:18215088; https://doi.org/http://dx.doi.org/10.2165/00063030-200822010-00003
- Schaffer AC, Lee JC. Vaccination and passive immunisation against Staphylococcus aureus. Int J Antimicrob Agents 2008; 32 Suppl 1:S71-8; PMID:18757184; https://doi.org/http://dx.doi.org/10.1016/j.ijantimicag.2008.06.009
- Botelho-Nevers E, Verhoeven P, Paul S, Grattard F, Pozzetto B, Berthelot P, Lucht F. Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage. Expert Rev Vaccines 2013; 12:1249-59; PMID:24111513; https://doi.org/http://dx.doi.org/10.1586/14760584.2013.840091
- Levy J, Licini L, Haelterman E, Moris P, Lestrate P, Damaso S, Van Belle P, Boutriau D. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial. Hum Vaccin Immunother 2015; 11:620-31; PMID:25715157; https://doi.org/http://dx.doi.org/10.1080/21645515.2015.1011021
- Giersing BK, Dastgheyb SS, Modjarrad K, Moorthy V. Status of vaccine research and development of vaccines for Staphylococcus aureus. Vaccine 2016; 34(26):2962-6
- Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. Targeting of α-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 2010; 202:1050-8; PMID:20726702; https://doi.org/http://dx.doi.org/10.1086/656043
- Karauzum H, Adhikari RP, Sarwar J, Devi VS, Abaandou L, Haudenschild C, Mahmoudieh M, Boroun AR, Vu H, Nguyen T, et al. Structurally designed attenuated subunit vaccines for S. aureus LukS-PV and LukF-PV confer protection in a mouse bacteremia model. PLoS One 2013; 8:e65384; PMID:23762356; https://doi.org/http://dx.doi.org/10.1371/journal.pone.0065384
- Brown EL, Dumitrescu O, Thomas D, Badiou C, Koers EM, Choudhury P, Vazquez V, Etienne J, Lina G, Vandenesch F, et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect 2009; 15:156-64; https://doi.org/http://dx.doi.org/10.1111/j.1469-0691.2008.02648.x
- Berube BJ, Bubeck Wardenburg J. Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins 2013; 5:1140-66; PMID:23888516; https://doi.org/http://dx.doi.org/10.3390/toxins5061140
- Kennedy AD, Wardenburg JB, Gardner DJ, Long RD, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. Targeting of α-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 2010; 202:1050-8; PMID:20726702; https://doi.org/http://dx.doi.org/10.1086/656043
- Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, Johnson JK, Nguyen C, Chen WH, Roghmann MC. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis 2012; 206:915-23; PMID:22807524; https://doi.org/http://dx.doi.org/10.1093/infdis/jis462
- Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 2013; 56:1554-61; PMID:23446627; https://doi.org/http://dx.doi.org/10.1093/cid/cit123
- Genestier AL, Michallet MC, Prevost G, Bellot G, Chalabreysse L, Peyrol S, Thivolet F, Etienne J, Lina G, Vallette FM, et al. Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. J Clin Invest 2005; 115:3117-27; PMID:16276417; https://doi.org/http://dx.doi.org/10.1172/JCI22684
- Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Vandenesch F, Etienne J. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128-32; PMID:10524952; https://doi.org/http://dx.doi.org/10.1086/313461
- Konig B, Prevost G, Piemont Y, Konig W. Effects of Staphylococcus aureus leukocidins on inflammatory mediator release from human granulocytes. J Infect Dis 1995; 171:607-13; PMID:7533198; https://doi.org/http://dx.doi.org/10.1093/infdis/171.3.607
- Konig B, Koller M, Prevost G, Piemont Y, Alouf JE, Schreiner A, Konig W. Activation of human effector cells by different bacterial toxins (leukocidin, alveolysin, and erythrogenic toxin A): generation of interleukin-8. Infect Immunity 1994; 62:4831-7; PMID:7927762
- Hensler T, Konig B, Prevost G, Piemont Y, Koller M, Konig W. Leukotriene B4 generation and DNA fragmentation induced by leukocidin from Staphylococcus aureus: protective role of granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF for human neutrophils. Infect Immunity 1994; 62:2529-35; PMID:7514577
- Yoong P. Enhancement of bacterial virulence by antibody neutralization of immune-activating toxins. Virulence 2010; 1:409-13; PMID:21178480; https://doi.org/http://dx.doi.org/10.4161/viru.1.5.12705
- Croze M, Dauwalder O, Dumitrescu O, Badiou C, Gillet Y, Genestier AL, Vandenesch F, Etienne J, Lina G. Serum antibodies against Panton-Valentine leukocidin in a normal population and during Staphylococcus aureus infection. Clin Microbiol Infect 2009; 15:144-8; PMID:19154491; https://doi.org/http://dx.doi.org/10.1111/j.1469-0691.2008.02650.x
- Brown EL, Dumitrescu O, Thomas D, Badiou C, Koers EM, Choudhury P, Vazquez V, Etienne J, Lina G, Vandenesch F, et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin Microbiol Infect 2009; 15:156-64; https://doi.org/http://dx.doi.org/10.1111/j.1469-0691.2008.02648.x
- Nissen M, Marshall H, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber W, et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine 2015; 33:1846-54; PMID:25707693; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2015.02.024
- Fattom A, Fuller S, Propst M, Winston S, Muenz L, He D, Naso R, Horwith G. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 2004; 23:656-63; PMID:15542186; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2004.06.043
- Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 2011; 11:505-18; PMID:21720387; https://doi.org/http://dx.doi.org/10.1038/nri3010
- Niebuhr M, Mamerow D, Heratizadeh A, Satzger I, Werfel T. Staphylococcal α-toxin induces a higher T cell proliferation and interleukin-31 in atopic dermatitis. Int Arch Allergy Immunol 2011; 156:412-5; PMID:21832830; https://doi.org/http://dx.doi.org/10.1159/000323905
- Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, Magorien JE, Blauvelt A, Kolls JK, Cheung AL, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010; 120:1762-73; PMID:20364087; https://doi.org/http://dx.doi.org/10.1172/JCI40891
- Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, Long RD, Dorward DW, Gardner DJ, Lina G, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006; 194:1761-70; PMID:17109350; https://doi.org/http://dx.doi.org/10.1086/509506
- Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008; 198:1166-70; PMID:18729780; https://doi.org/http://dx.doi.org/10.1086/592053
- Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, Barbu EM, Vazquez V, Höök M, Etienne J, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315:1130-3; PMID:17234914; https://doi.org/http://dx.doi.org/10.1126/science.1137165
- Zivkovic A, Sharif O, Stich K, Doninger B, Biaggio M, Colinge J, Bilban M, Mesteri I, Hazemi P, Lemmens-Gruber R, et al. TLR 2 and CD14 mediate innate immunity and lung inflammation to staphylococcal Panton-Valentine leukocidin in vivo. J Immunol 2011; 186:1608-17; https://doi.org/http://dx.doi.org/10.4049/jimmunol.1001665
- Loffler B, Hussain M, Grundmeier M, Bruck M, Holzinger D, Varga G, Roth J, Kahl BC, Proctor RA, Peters G. Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathogens 2010; 6:e1000715; PMID:20072612; https://doi.org/http://dx.doi.org/10.1371/journal.ppat.1000715
- Spaan AN, Schiepers A, de Haas CJ, van Hooijdonk DD, Badiou C, Contamin H, Vandenesch F, Lina G, Gerard NP, Gerard C, et al. Differential interaction of the staphylococcal Toxins Panton-Valentine Leukocidin and gamma-hemolysin CB with human C5a Receptors. J Immunol 2015; 195:1034-43; https://doi.org/http://dx.doi.org/10.4049/jimmunol.1500604
- Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ. Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections. Trends Pharmacological Sci 2016; 37:231-41; PMID:26719219; https://doi.org/http://dx.doi.org/10.1016/j.tips.2015.11.008
- Rouha H, Badarau A, Visram ZC, Battles MB, Prinz B, Magyarics Z, Nagy G, Mirkina I, Stulik L, Zerbs M, et al. Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. Mabs 2015; 7:243-54; PMID:25523282; https://doi.org/http://dx.doi.org/10.4161/19420862.2014.985132